Swiss Auto Components Stock News

SWX:CLN
SWX:CLNChemicals

Assessing Clariant (SWX:CLN) Valuation After Recent Share Pullback And Mixed Long Term Returns

Recent share performance and business snapshot Clariant (SWX:CLN) has come into focus after a recent pullback, with the stock down about 7% over the past month and roughly 7% over the past 3 months, prompting investors to reassess its fundamentals. The Switzerland based specialty chemicals company operates across three main segments: Care Chemicals, Catalysts, and Adsorbents & Additives, serving customers across Europe, the Americas, Asia and the Middle East & Africa. See our latest analysis...
SWX:HBAN
SWX:HBANInsurance

European Stocks Estimated To Be Up To 30.8% Below Their Intrinsic Value

The European stock market recently experienced a volatile week, with modest gains in the pan-European STOXX Europe 600 Index, as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. added pressure to markets. In this context, identifying undervalued stocks becomes crucial for investors seeking opportunities that are potentially trading below their intrinsic value amidst fluctuating market...
SWX:AMS
SWX:AMSSemiconductor

Is ams-OSRAM's (SWX:AMS) AI Photonics Pivot Offsetting Softer 2026 Guidance?

In early May 2026, ams-OSRAM reported first-quarter sales of €796 million alongside a larger net loss and issued guidance for slightly softer full-year 2026 revenue due to business divestments and foreign-exchange effects. At the same time, the company highlighted progress in its Digital Photonics pivot, including a development partnership targeting AI data centers and micro LED commercialization, which has drawn renewed attention to its semiconductor portfolio. We’ll now examine how this...
SWX:VATN
SWX:VATNBanks

Why Valiant Holding (SWX:VATN) Is Down 8.4% After Q1 Results Expose Debt Concerns

Valiant Holding AG reported first-quarter 2026 results with net interest income of CHF 100.64 million and net income of CHF 33.24 million, both slightly higher than a year earlier. Despite this modest improvement, investors focused on the bank’s elevated debt levels and challenging revenue trends, which raised concerns about its financial flexibility and resilience. We’ll now examine how these weaker-than-expected earnings, alongside concerns over the high debt-to-equity ratio, shape Valiant...
SWX:KURN
SWX:KURNBiotechs

Assessing Kuros Biosciences (SWX:KURN) Valuation After Recent Share Price Weakness

Why Kuros Biosciences (SWX:KURN) is on investors’ radar today Kuros Biosciences (SWX:KURN) has drawn attention after recent share price pressure, with the stock showing a 15.1% decline over the past month and a 20.2% decline over the past 3 months. See our latest analysis for Kuros Biosciences. At the latest share price of CHF20.12, Kuros Biosciences shows weaker short term momentum, with a 1 month share price return of 15.1% decline and a year to date share price return of 24.6% decline,...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis Expands US RLT Network As Denton Build Tests Growth Story

Novartis has started construction on a new radioligand therapy manufacturing facility in Denton, Texas. The Denton site expands the company’s US network for advanced cancer treatments and is part of a broader multi year, multi billion dollar US investment plan. The project is expected to support access to personalized cancer therapies and create jobs in bioengineering and advanced manufacturing. For investors following Novartis (SWX:NOVN), the Denton build out comes as the stock trades...
SWX:UBSG
SWX:UBSGCapital Markets

Is UBS Group (SWX:UBSG) Still Attractive After Credit Suisse Integration Progress And Strong 5-Year Run?

If you are asking whether UBS Group is priced attractively right now, the starting point is to look closely at what the current share price might already be assuming. The stock last closed at CHF 35.03, with returns of 1.5% over 7 days, 8.1% over 30 days, a 8.2% decline year to date, and gains of 38.4% over 1 year, 120.8% over 3 years and 189.1% over 5 years. Recent headlines have focused on UBS Group's role as a major global banking and wealth management group, including its ongoing...
SWX:TEMN
SWX:TEMNSoftware

Is It Time To Reassess Temenos (SWX:TEMN) After Mixed Returns And DCF Upside Signals

If you are wondering whether Temenos is priced fairly or if the current share price leaves room for upside, it helps to start by looking closely at what the market has been paying for this stock recently. Temenos shares recently closed at CHF 74.20, with returns of 0.4% over 7 days, 2.3% over 30 days, a 9.0% decline year to date, and 22.6% over the past year. Together, these figures present a mixed picture of changing expectations and risk perception. Recent coverage of Temenos has focused...
SWX:ALC
SWX:ALCMedical Equipment

Is Alcon (SWX:ALC) Starting To Look Interesting After A Steep Share Price Slump

If you are wondering whether Alcon at around $49.17 is starting to look like value after a tough spell, this breakdown will help you frame the opportunity and the risks. The stock has faced sharp share price pressure, with returns of a 15.5% decline over 7 days, a 19.7% decline over 30 days, a 22.6% decline year to date and a 37.9% decline over 1 year, as well as a 29.9% decline over 3 years and a 19.2% decline over 5 years. Recent coverage has focused on how this sustained weakness has put...
SWX:UBSG
SWX:UBSGCapital Markets

UBS Weighs US Acquisitions As Credit Suisse Integration Shifts Valuation Story

UBS Group is signaling interest in expanding in the US through acquisitions following its integration of Credit Suisse. Leadership is highlighting growth ambitions in the Americas and pointing to recent inflows of new client assets in the region. The group has received a national US banking license and announced executive hires in key US regions to support potential expansion. UBS Group (SWX:UBSG) is trading around CHF34.94, with the stock up 39.1% over the past year and 190.3% over five...
SWX:ALC
SWX:ALCMedical Equipment

A Look At Alcon (SWX:ALC) Valuation After Earnings Miss And New US$1.5b Buyback

Earnings miss, weaker profit, and new buyback sharpen focus on Alcon stock Alcon (SWX:ALC) reported first quarter 2026 revenue growth supported by recent product launches and market share gains. Profit came under pressure, guidance was reaffirmed, and a US$1.5b share repurchase plan was introduced. See our latest analysis for Alcon. Alcon's latest earnings and the new US$1.5b buyback have coincided with a sharp reset in sentiment, with a 7 day share price return of a 13.6% decline and a 1...
SWX:LOGN
SWX:LOGNTech

Assessing Whether Logitech International (SWX:LOGN) Still Looks Undervalued After Recent Share Price Momentum

Why Logitech International (SWX:LOGN) is on investors’ radar today Logitech International (SWX:LOGN) has drawn interest after recent price moves, including a 1 day return of about a 0.4% decline and gains of roughly 3.6% over the past week and 8.9% over the past month. See our latest analysis for Logitech International. Looking beyond the latest move, Logitech’s 15.1% 90 day share price return and 27.8% 1 year total shareholder return point to momentum that contrasts with a relatively flat...
SWX:ALC
SWX:ALCMedical Equipment

Alcon (SWX:ALC) Margin Compression Challenges Bullish Earnings Growth Narratives

Alcon (SWX:ALC) opened 2026 with Q1 revenue of US$2.7b and basic EPS of US$0.39, setting a clear marker for how the year is starting after a period where trailing 12 month revenue sat at US$10.6b and EPS at US$1.67. Over recent quarters, the company has seen revenue move from US$2.5b in Q4 2024 to around US$2.7b in Q1 2026, while quarterly EPS has ranged from US$0.36 to US$0.71. This gives investors a wide set of earnings outcomes to weigh against a reported trailing net margin of 7.7% and...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is It Too Late To Consider Novartis (SWX:NOVN) After Its 3 Year 41.9% Rise?

Investors may be wondering if Novartis at CHF113.54 is still offering value, or if most of the easy gains are already on the table. The stock is up 25.9% over the last year and 41.9% over 3 years, even though it shows a 1% decline over 7 days, a 7.8% decline over 30 days, and a 4.6% return year to date. Recent headlines have focused on Novartis as a large global pharmaceutical business, with investors watching how its product portfolio and pipeline shape long term expectations. This context...
SWX:TEMN
SWX:TEMNSoftware

Temenos Wins Global SaaS Deals As Cloud Strategy And Valuation Attract Attention

Temenos (SWX:TEMN) has secured new SaaS core banking agreements with First Abu Dhabi Bank in Saudi Arabia and Questrade in Canada. The company is expanding its SaaS offering on Amazon Web Services to cover end to end digital banking and payments. These updates relate to Temenos' cloud banking platform and its global client reach across the Middle East and North America. For Temenos, a provider of core banking and digital banking software, these wins highlight how large banks and non bank...
SWX:BANB
SWX:BANBLife Sciences

A Look At Bachem Holding (SWX:BANB) Valuation After Chief Commercial Officer Departure News

Bachem Holding (SWX:BANB) is back in focus after announcing the departure of Chief Commercial Officer Torsten Wöhr. CEO Anne-Kathrin Stoller is set to temporarily assume commercial responsibilities from May 25, 2026. See our latest analysis for Bachem Holding. The leadership change comes as Bachem Holding’s share price trades at CHF75.45, with a 7 day share price return of 10.71% and a year to date share price return of 29.08%. The 1 year total shareholder return of 54.39% contrasts with a 3...
SWX:TEMN
SWX:TEMNSoftware

A Look At Temenos (SWX:TEMN) Valuation After Q1 Growth And New CFO Appointment

Temenos (SWX:TEMN) has just paired a first quarter earnings update with a change in its finance leadership, providing fresh information on both its recent financial performance and how the company is organizing for future execution. See our latest analysis for Temenos. At a share price of CHF75.0, the stock has recovered from a softer start to the year, with a 90 day share price return of 16.64% and a 1 year total shareholder return of 27.33%. This suggests that recent momentum has been...
SWX:IDIA
SWX:IDIABiotechs

Idorsia (SWX:IDIA) Valuation Check After QUVIVIQ Guidance And First Quarter 2026 Update

What Idorsia’s new QUVIVIQ guidance tells you Idorsia (SWX:IDIA) has put QUVIVIQ at the center of its 2026 outlook, guiding for CHF 200 million in sales after releasing its first quarter results and updating progress on its broader pipeline and partnerships. See our latest analysis for Idorsia. Following the first quarter update and QUVIVIQ guidance, Idorsia’s recent share price moves look mixed, with a 30 day share price return of 8.16% but a year to date share price return of a 6.35%...
SWX:ROP
SWX:ROPPharmaceuticals

Roche Holding (SWX:ROP) Valuation Check After Recent Share Price Weakness And Pullback

Roche Holding stock: recent move puts long term returns in context Roche Holding (SWX:ROP) has drawn attention after a recent pullback, with the stock down about 0.6% over the past day and just over 1% over the past week. For readers tracking longer horizons, the share price shows a small decline over the past month and a larger negative move over the past 3 months, while multi year total returns remain positive. See our latest analysis for Roche Holding. At a share price of CHF316.5, Roche...